Conclusions on the cost-effectiveness of pembrolizumab monotherapy compared with platinum-based chemotherapy for patients with first-line advanced, high PD-L1 expression (≥50%) NSCLC without EGFR or ALK mutations were reported in eight studies that modeled data from the KEYNOTE-024 trial. This evidence concerns the gene ALK and non-small cell lung carcinoma.